Advertisement

Topics

Advaxis drops after clinical hold due to patient death

05:11 EDT 13 Mar 2018 | BioPharmaDive

The death led the FDA to halt enrollment and dosing in a trial testing Advaxis' drug with Imfinzi, but analysts suggest AstraZeneca's drug could be the culprit.

Original Article: Advaxis drops after clinical hold due to patient death

NEXT ARTICLE

More From BioPortfolio on "Advaxis drops after clinical hold due to patient death"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...